EnWave Appoints New Independent Director and Grants Stock Options

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan. 27, 2014) - EnWave Corporation (TSX VENTURE:ENW) (FRANKFURT:E4U) ("EnWave", or the "Company") announced today that it has appointed Mr. Hugh McKinnon as a Non-Executive Independent Director to join the seven current Directors sitting on EnWave's Board. Mr. McKinnon is a very knowledgeable senior-level executive that has Director's experience from serving on the Boards of several other publically traded companies.

Mr. McKinnon is a current Director and shareholder of Norscot Investments Ltd., a privately held company with extensive interests in media and residential/commercial developments in Washington, Alaska, British Columbia and Alberta. He also has served as former Chairman of the Board (from 2000-2005) of Rainmaker Entertainment Inc. and has been a Director of Premium Brands Holdings Corporation since January 1^st, 2007, which owns a broad range of leading specialty food manufacturing and differentiated food distribution businesses.

Additionally, EnWave announced today that it has granted a total of 300,000 stock options (150,000 stock options each) to its two newest Directors, Mr. McKinnon and Dr. Stewart Ritchie, pursuant to its Share Option Plan (the "Plan"). Each option will entitle its holder to purchase one common share of the Company at an exercise price of $1.40 per share for a period of five years from this date. The options will vest in accordance to provisions set out in the Plan, or as otherwise required by the TSX Venture Exchange. The grant is subject to regulatory approval.

"Hugh McKinnon brings a wealth of public market and business experience that should specifically benefit EnWave," stated Dr. Tim Durance, Chairman and Co-CEO of EnWave. "As Chairman, I am thrilled to have a Director of his caliber join the Board."

About EnWave

EnWave Corporation is a Vancouver-based industrial technology company developing commercial applications for its proprietary Radiant Energy Vacuum (REV™) dehydration technology. EnWave aims to sign royalty-bearing commercial licenses with leading food and pharmaceutical companies for the use of its revolutionary technology. Thus far the Company has signed commercial licenses with Bonduelle, a global leader in the production of vegetables, for the processing of dehydrofrozen vegetables; Hormel Foods Corporation, a major processed meat manufacturer, for the production of healthy dried meat products; Milne Fruit Product, EnWave's first major licensee, for the production of several dehydrated fruit and vegetable products in the whole, fragmented and powdered form; a leading North American enzyme company, to dehydrate a series of food-related enzymes for their Tier 1 clients; and Napa Mountain Spice Company, to dry high-quality California bay leaves. In addition to these licenses, EnWave has formed a Limited Liability Partnership with Lucid Capital Management to develop, manufacture, market and sell all-natural cheese snack products in the United States under the Moon Cheese^® brand.

Also, EnWave has entered into a wide range of research and collaboration agreements with an expanding list of multinational companies, including Nestlé, Kellogg's, Grupo Bimbo, Grimmway Farms, Ocean Spray Cranberries, Cherry Central, Sun-Maid Growers, Gay Lea Foods, R.J. Reynolds and Merck. EnWave is introducing REV™ as a new dehydration standard in the food and biological material sectors: potentially faster and cheaper than freeze drying, with better end product quality than air drying or spray drying.

EnWave currently has six REV™ platforms: commercial-scale nutraREV^® and MIVAP^® are used in the food industry to dry fruits, vegetables, meat, herbs and seafood quickly and at low-cost, while maintaining high levels of nutrition, taste, texture and colour. The Company is also developing powderREV™ for bulk dehydration of food cultures, probiotics and fine biochemicals such as enzymes; quantaREV™ for continuous, high-volume low-temperature drying of pastes, gels, liquids, or particulates; and bioREV™ and freezeREV™ as new methods to stabilize and dehydrate biopharmaceuticals such as vaccines and antibodies. More information about EnWave is available at www.enwave.net.

EnWave Corporation

Dr. Tim Durance, Chairman & Co-CEO

Safe Harbour for Forward-Looking Information Statements: This press release may contain forward-looking information based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures, and the expected synergies following the closing are forward-looking statements. All third party references to market information in this release are not guaranteed to be accurate as the Company did not conduct the original primary research. These statements are not a guarantee of future performance and involve a number of risks, uncertainties and assumptions. Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.